Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance - PubMed (original) (raw)

Clinical Trial

Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance

J F Setaro et al. Am J Cardiol. 1990.

Abstract

Normal left ventricular systolic performance with impaired left ventricular diastolic filling may be present in a substantial number of patients with congestive heart failure (CHF). To evaluate the effect of oral verapamil in this subset, 20 men (mean age 68 +/- 5 years) with CHF, intact left ventricular function (ejection fraction greater than 45%) and abnormal diastolic filling (peak filling rate less than 2.5 end-diastolic volumes per second [edv/s]) were studied in a placebo-controlled, double-blind 5-week crossover trial. All patients underwent echocardiography to rule out significant valvular disease, and thallium-201 stress scintigraphy to exclude major active ischemia. Compared to baseline values, verapamil significantly improved exercise capacity by 33% (13.9 +/- 4.3 vs 10.7 +/- 3.4 minutes at baseline) and peak filling rate by 30% (2.29 +/- 0.54 vs 1.85 +/- 0.45 edv/s at baseline) (all p less than 0.05). Placebo values were 12.3 +/- 4.0 minutes and 2.16 +/- 0.48 edv/s, respectively (difference not significant for both). Improvement from baseline in an objective clinico-radiographic heart failure score (scale 0 to 13) was significantly greater with verapamil compared to placebo (median improvement in score: 3 vs 1, p less than 0.01). Mean ejection fraction and systolic blood pressure were unchanged from baseline; diastolic blood pressure and heart rate decreased to a small degree. Verapamil may have therapeutic efficacy in patients with CHF, preserved systolic function and impaired diastolic filling.

PubMed Disclaimer

Cited by

Effects of calcium channel blockers in patients with heart failure with preserved ejection fraction: A protocol for systematic review and meta-analysis.
Fukuta H, Goto T, Kamiya T. Fukuta H, et al. PLoS One. 2024 Aug 19;19(8):e0307258. doi: 10.1371/journal.pone.0307258. eCollection 2024. PLoS One. 2024. PMID: 39159218 Free PMC article.
Relationship between _β_1-AA and AT1-AA and Cardiac Function in Patients with Hypertension Complicated with Left Ventricular Diastolic Function Limitation.
Wang L, Lv XB, Yuan YT, Wang N, Yao HY, Zhang WC, Yin PF, Liu XH. Wang L, et al. Cardiovasc Ther. 2023 Dec 13;2023:7611819. doi: 10.1155/2023/7611819. eCollection 2023. Cardiovasc Ther. 2023. PMID: 38125703 Free PMC article.
Sex Differences in the Anti-Hypertensive Effect of Calcium-Channel Blockers: A Systematic Review and Meta-Analysis.
van Luik EM, Vaes EWP, Vesseur MAM, Wilmes N, Meijs DAM, Laven SAJS, Mohseni-Alsalhi Z, de Haas S, Spaanderman MEA, Ghossein-Doha C. van Luik EM, et al. Biomedicines. 2023 Jun 2;11(6):1622. doi: 10.3390/biomedicines11061622. Biomedicines. 2023. PMID: 37371717 Free PMC article. Review.
Heart Failure with Preserved Ejection Fraction in Children.
Das B, Deshpande S, Akam-Venkata J, Shakti D, Moskowitz W, Lipshultz SE. Das B, et al. Pediatr Cardiol. 2023 Mar;44(3):513-529. doi: 10.1007/s00246-022-02960-7. Epub 2022 Aug 17. Pediatr Cardiol. 2023. PMID: 35978175 Review.
Therapeutic Approaches in Heart Failure with Preserved Ejection Fraction (HFpEF) in Children: Present and Future.
Das BB. Das BB. Paediatr Drugs. 2022 May;24(3):235-246. doi: 10.1007/s40272-022-00508-z. Epub 2022 May 2. Paediatr Drugs. 2022. PMID: 35501560 Review.

Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance - PubMed (original) (raw)